Business
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen ATLANTA, GA - April 2, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc.
About this update from Geovax Labs, Inc.
[{"type":"text","content":"MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen\nATLANTA, GA - April 2, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today highlighted preclinical data presented at the World Vaccine Congress Washington 2026 supporting the potential for a single-dose Modified Vaccinia Ankara (MVA)-based mpox vaccine. The data demonstrate that a novel MVA vaccine construct incorporating an immunomodulatory peptide (\"MVA-X\") achieved protective efficacy, comparable to the traditional two-dose MVA regimen, in a murine orthopoxvirus challenge model.\n The presentation, titled \"Next-Generation MVA Mpox Vaccines: Harnessing an Immunomodulatory Peptide for Single-Dose Efficacy,\" was delivered by Heather Koehler, Ph.D., of Washington State University, during the Immune Profiling track on April 1, 2026.\n Single-dose efficacy: the MVA-X vaccine construct achieved complete protection comparable to a two-dose MVA vaccine regimen in a lethal orthopox challenge model, while a single-administration of MVA showed only partial protection.\n Durable protection: Protective immunity was maintained through Day 150 post-vaccination, with 100% survival observed in both MVA-X (single-dose) and two-dose MVA groups.\n Robust viral control: MVA-X demonstrated significant reduction in lung viral burden, comparable to the two-dose MVA regimen.\n Improved clinical outcomes: MVA-X vaccinated animals exhibited minimal weight loss, reduced disease severity, and preserved lung structure.\n T cell-driven immunity: Protection in MVA-X vaccinated animals was independent of neutralizing antibodies, supported by enhanced CD4+ and CD8+ T cell responses.\n \n Mechanistic Innovation\nThe MVA-X construct incorporates a peptide designed to transiently modulate the PD-1 immune checkpoint pathway, enhancing T cell activation and durability of immune response during vaccination.\nThis approach enables:\n Stronger and more sustained T cell responses\n Enhanced immune memory\n Potential for durable protection with fewer doses\n \n This represents a novel application of immune checkpoint modulation within vaccine design.\n\"These findings provide an important proof-of-concept that the performance of MVA-based vaccines can be...